- Home
- YMT vs MRSN Comparison
YMT vs MRSN Comparison
Compare YMT & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YMT | MRSN |
|---|---|---|
| Founded | 2011 | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.7M | 138.8M |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | YMT | MRSN |
|---|---|---|
| Price | $1.57 | $28.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $30.38 |
| AVG Volume (30 Days) | 54.0K | ★ 79.6K |
| Earning Date | 06-09-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $20,502,945.00 | ★ $33,180,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $5.21 |
| 52 Week High | $6.05 | $37.88 |
Technical Indicators
Market Signals| Indicator | YMT | MRSN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 75.95 |
| Support Level | N/A | $28.11 |
| Resistance Level | N/A | $29.15 |
| Average True Range (ATR) | 0.00 | 0.47 |
| MACD | 0.00 | -0.54 |
| Stochastic Oscillator | 0.00 | 47.29 |
Price Performance
Historical ComparisonAbout YMT Yimutian Inc. American Depositary Shares
Yimutian Inc is the largest agricultural B2B platform in mainland China. It provide a comprehensive set of digital solutions to facilitate agricultural product transactions, ranging from searching, matching, to transaction facilitation and settlement. The company pride itself as the go-to platform for merchants by leveraging its inventive technology and industry know-how. Its platform had over 38 million merchants. It has also established approximately 12 offline stores in mainland China to trade agricultural products at cultivation and production sites with sellers and buyers.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.